Clinical trials in Kiel – page 9

433 clinical trials in Kiel, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Kiel at a glance

433

clinical trials

Research sites2

Quick filters

433 trials in Kiel

Open in trial search

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Acute myeloid leukaemia+2

Recruiting

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ivosidenib
Sponsor:Technische Universitat Dresden

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Celgene Corp.

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Heidelberg University

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:University Of Cologne

Contact Research Centre

Acute myeloid leukaemia+1

Recruiting

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fludarabine
Sponsor:Technische Universitat Dresden

Contact Research Centre

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Obefazimod
Sponsor:Abivax

Contact Research Centre

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Chronic lymphocytic leukaemia+3

Recruiting

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic graft versus host disease

Recruiting

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Axatilimab
Sponsor:Incyte Corp.

Contact Research Centre

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AGO Research GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Kiel

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of ribociclib with endocrine therapy for HR-positive, HER2-negative cases. Additional research encompasses various blood cancers, including lymphomas and leukemia.

Early-stage breast cancer therapy
Diffuse large B-cell lymphoma treatments
Acute myeloid leukemia management

Cutting-edge research evaluating novel therapeutic combinations and treatment approaches for better patient outcomes.

02 Dermatological Studies

Comprehensive research into chronic skin conditions, including trials for plaque psoriasis and atopic dermatitis. Studies evaluate new therapeutic agents for moderate to severe cases.

Hidradenitis suppurativa treatments
Novel psoriasis therapies
Atopic dermatitis management

Focus on developing effective treatments for persistent skin conditions that significantly impact quality of life.

03 Gastrointestinal Research

Advanced studies in inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Trials investigate innovative therapies for moderate to severe cases.

Long-term disease management
Combination therapy approaches
Treatment-resistant cases

Investigation of new therapeutic options for patients with inadequate response to conventional treatments.

Back to Germany All countries